Safety procedure revision notice for thalidomide, lenalidomide and pomalidomide products
「サリドマイド製剤、レナリドミド製剤及びポマリドミド製剤の使用に当たっての安全管理手順の改訂について（周知依頼）」を掲載しました
Published: 2025-02-18 · Source: Pharmaceuticals and Medical Devices Agency (PMDA) — Safety Updates · Stage: Government Announcement · Area: Healthcare / Pharmaceuticals · Impact (preliminary): Low · First detected by this dashboard: 2026-08-06
View the original Japanese source More Healthcare / Pharmaceuticals updates Search all updates in the dashboard
AI summary
Generated by AI from the Japanese source metadata. It is an unofficial monitoring aid, not legal advice, and may contain errors. The area, stage, and impact labels are preliminary keyword-based triage labels. Confirm every point in the original Japanese source.
Summary
On 2025-02-18, the Pharmaceuticals and Medical Devices Agency (PMDA) announced the posting of a notice requesting dissemination of revised safety management procedures for the use of thalidomide, lenalidomide and pomalidomide products. The title does not specify the procedural changes or their implementation date.
Business Impact
Healthcare professionals using thalidomide, lenalidomide or pomalidomide products may be affected by changes to the safety management procedures for their use.
Recommended Action
Review of the official Japanese notice could clarify the revised procedures, their intended recipients and any implementation timing.